Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2007-04-16
2010-02-02
Ouspenski, Ilia (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
Reexamination Certificate
active
07655229
ABSTRACT:
The present application describes antibodies that selectively bind human FcγRIIB, with little or no binding to other human FcγRs, e.g., human FcγRIIA. The invention also provides isolated bispecific antibodies comprising an antibody that selectively binds FcγRIIB, and a second antibody that specifically binds an activating receptor. Various uses, including therapeutic uses, for those antibodies are also described, including administration with anti-tumor antibodies and methods of inhibiting immune responses and suppressing histamine release.
REFERENCES:
patent: 4515893 (1985-05-01), Kung et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5091313 (1992-02-01), Chang
patent: 5500362 (1996-03-01), Robinson et al.
patent: 5622700 (1997-04-01), Jardieu et al.
patent: 5672347 (1997-09-01), Aggarwal et al.
patent: 5693762 (1997-12-01), Queen et al.
patent: 5714338 (1998-02-01), Wai Fei et al.
patent: 5721108 (1998-02-01), Robinson et al.
patent: 5725856 (1998-03-01), Hudziak et al.
patent: 5731168 (1998-03-01), Carter et al.
patent: 5736137 (1998-04-01), Anderson et al.
patent: 5807706 (1998-09-01), Carter et al.
patent: 5821333 (1998-10-01), Carter et al.
patent: 5821337 (1998-10-01), Carter et al.
patent: 5840523 (1998-11-01), Simmons et al.
patent: 7138494 (2006-11-01), Endou et al.
patent: 7276585 (2007-10-01), Lazar et al.
patent: 2003/0077282 (2003-04-01), Bigler et al.
patent: 2006/0193857 (2006-08-01), Boruchov et al.
patent: 0 420 937 (1994-11-01), None
patent: 93/04173 (1993-03-01), None
patent: 95/19181 (1995-07-01), None
patent: 95/23865 (1995-09-01), None
patent: 96/30046 (1996-10-01), None
patent: 96/40210 (1996-12-01), None
patent: 97/26912 (1997-07-01), None
patent: 98/06248 (1998-02-01), None
patent: 98/23761 (1998-06-01), None
patent: 98/45331 (1998-10-01), None
patent: 98/51793 (1998-11-01), None
patent: 99/01556 (1999-01-01), None
patent: 00/29431 (2000-05-01), None
patent: 00/75348 (2000-12-01), None
patent: 01/40309 (2001-06-01), None
patent: 01/79299 (2001-10-01), None
patent: 02/088317 (2002-11-01), None
patent: 02/102320 (2002-12-01), None
patent: 03/066095 (2003-08-01), None
patent: 2004/016750 (2004-02-01), None
patent: 2005/018669 (2005-03-01), None
patent: 2005/110474 (2005-11-01), None
patent: 2005/115452 (2005-12-01), None
patent: 2006/066078 (2006-06-01), None
Heaney et al., Lancet, 2005, 365: 974-976.
Atwell et al., J. Mol. Biol., 1997, 270: 26-35.
Kepley et al., J. Biol. Chem., 2004, 279: 35139-35149.
Asano et al., “L-Type Amino Acid Transporter-1 Expressed in Human Astrocytomas, U343MGa”Biol. Pharm. Bull. 30 (3) :415-422 (Mar. 2007).
Bae et al., “Y+ amd y+L Arginine Transporters in Neuronal Cells Expressing Tyrosine Hydroxylase”Biochimica et Biophysica Acta1745:65-73 (2005).
Berg et al., “Bispecfic Antibodies that Mediate Killing of Cells Infected with Human Immunodeficiency Virus of Any Strain”Proc. Natl. Acad. Sci. USA88:4723-4727 (Jun. 1991).
Bik-Multanowski et al., “LAT1 Gene Variants—Potential Factors Influencing the Clinical Course of Phenylketonuria”J. Inherit. Metab. Dis. 29:684 (2006).
Bleehan et al., “A Randomised Trial of Three or Six Courses of Etoposide Cyclophosphamide Methotrexate and Vincristine or Six Courses of Etoposide and Ifosfamide in Small Cell Lung Cancer (SCLC) II: Quality of Life”MRC Lung Cancer Workirg Partypp. 1157-1166.
Boado et al., “Human LAT1 Single Nucleotide Polymorphism N230K Does Not Alter Phenylalanine Transport”Molecular Genetics and Metabolism 83pp. 306-311 (2004).
Boado et al., “Site-Directed Mutagenesis of Cysteine Residues of Large Neutral Amino Acid Transporter LAT1”Biochimica et Biophysica Acta1715:104-110 (2005).
Boado et al., “Site-Directed Mutagenesis of Rabbit LAT1 at Amino Acids 219 and 234”Journal of Neurochemistry84:1322-1331 (2003).
Bobrova et al., “An Immunoglobulin-like Antigen in Human Cell Lines and Sera of Cancer Patients”Neoplasma39 (2) :101-105 (1992).
Brust et al., “The Influx of Neutral Amino Acids into the Porcine Brain During Development: a Positron Emission Tomography Study”Developmental and Brain Research152: 241-253 (2004).
Bubnoff, D. et al., “The central role of FcεRI in allergy”Clinical&Experimental Dermatology28(2) :184-187 (2003).
Carter et al., “Humanization of an Anti-p185HER2Antibody for Human Cancer Therapy”Proc. Natl. Acad. Sci. USA89(10) :4285-4289 (May 1992)
Ceriani et al., “Biological activity of two humanized antibodies against two different breast cancer antigens and comparison to their original murine forms”Cancer Research55(23) :5852s-5856s (1995).
Chamow et al., “A Humanized, Bispecific Immunoadhesin-Antibody That Retargets CD3+ Effectors to Kill HIV-1-Infected Cells”Journal of Immunology153(9) :4268-4280 (Nov. 1, 1994).
Choy et al., “Percentage of anti-cd4 monoclonal antibody-coated lymphocytes in the rheumatoid joint is associated with cilnical improvement”Arthritis Rheum. 39:52-56 (1996).
Clynes et al., “Fc Receptors Are Required in Passive and Active Immunity to Melanoma”Proc. Natl. Acad. Sci. USA95(2) :652-656 (Jan. 1998).
Clynes et al., “Modulation of immune complex-induced inflammation in vivo by the coordinate expression of activation and inhibitory Fc receptors”Journal of Experimental Medicine189(1):179-185 (Jan. 4, 1999).
Daeron, M. et al., “Regulation of high-affinity IgE receptor-mediated mast cell activation by murine low-affinity IgG receptors”J. Clin. Invest. 95:577-585 (1995).
Daeron, M. et al., “The same tyrosine-based inhibition motif, in the intracytoplasmic domain of FcγRIIB, regulates negatively Bcr-, Tcr-, and FcR-dependent cell activation”Immunity3:635-646 (1995).
Dhainaut et al., “CDP571, a humanized antibody to human tumor necrosis factor-alpha: Safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock”Crit. Care Med. 23(9):1461-1469 (1995).
Ellis et al., “Engineered anti-CD38 monoclonal antibodies for immunotherapy of multiple myeloma”European Journal of Immunology155:925-937 (1995).
Fraga et al., “Expression of LAT1 and LAT2 Amino Acid Transporters in Human and Rat Intestinal Epithelial Cells”Amino Acids29:229-233 (Jul. 20, 2005).
Gao et al., “Expression of Cdk5, p35, and Cdk5-Associated Kinase Activity in the Developing Rat Lens”Developmental Genetics20:267-275 (1997).
Gaugitsch et al., “A novel transiently expressed, integral membrane protein linked to cell activation. Molecular cloning via the rapid degradation signal AUUUA”J Biol Chem. 267(16) :11267-11273 (Jun. 5, 1992).
Graziano et al., “Construction and characterization of a humanized anti-γ-Ig receptor Type I (FcγRI) monoclonal antibody”J. Immunol. 155(10) :4996-5002 (1995).
Greenman et al., “Characterization of a new monoclonal anti-FcγRII antibody, AT10, and its incorporation into a biscpecific f(ab′)2derivative for recruitment of cytotoxic effectors”Molecular Immunology28:1243-1254 (1991).
Guazzi et al., “HMGB1, an Architectural Chromatin Protein and Extracellular Signalling Factor, Has a Spatially and Temporally Restricted Expression Pattern in Mouse Brain”Gene Expression Patterns3:29-33 (2003).
Guberan et al., “Disability, Mortality, and Incidence of Cancer Among Geneva Painters and Electricians: A Historical Prospective Study”British Journal of Industrial Medicine46:16-23 (1989).
Hourmant et al., “Administration of an Anti-CD11a Monoclonal Antibody in Recipients of Kidney Transplantation”Transplantation58(3) :377-380 (Aug. 1994).
Ierino et al., “Mapping epitopes of human FcγRII (CDw32) with monoclonal antibodies and recombinant receptors”J. Immunol. 150:1794-1803 (1993).
Jurcic et al., “Radiolabeled
Chan Andrew C.
Shields Robert L.
Wu Lawren
Ouspenski Ilia
Svoboda Craig G.
LandOfFree
Anti-FC-gamma RIIB receptor antibody and uses therefor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-FC-gamma RIIB receptor antibody and uses therefor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-FC-gamma RIIB receptor antibody and uses therefor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4190410